Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 1-7

  Master, Ronald N ^a   Deane, Jennifer ^b   Opiela, Carol ^b   Sahm, Daniel F ^b  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

Antibacterial; Cell envelope; Pathogens; Resistance

Indexed keywords

BETA LACTAM; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DATA BASE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STAPHYLOCOCCUS AUREUS;

EID: 84872858563     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12022     Document Type: Article

References (16)

1. Paterson, D.L. 2006. Resistancein gram-negative bacteria: enterobacteriaceae. Am. J. Med. 119: S20-S28; discussion S62-S70.
2. Livermore, D.M. 2007. Introduction: the challenge of multi-resistance. Int. J. Antimicrob. Agents 29(Suppl. 3): S1-S7.
3. Spellberg, B., R. Guidos, D. Gilbert, et al. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 155-164.
4. Talbot, G.H., J. Bradley, J.E. Edwards, Jr. et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42: 657-668.
5. Rice, L.B. 2009. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbial. 12: 476-481.
6. Rice, L.B. 2012. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin. Proc. 87: 198-208.
7. Rice, L.B. 2007. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve. Clin. J. Med. 74(Suppl. 4): S12-S20.
8. Rice, L.B. 2006 Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control 34(Suppl. 1): S11-S19; discussion S64-S73.
9. Bush, K., G.A. Jacoby 2010. Updated functional classification of {beta}-lactamases. Antimicrob. Agents Chemother. 54: 969-976.
10. Rice, L.B. 2010. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol. 31(Suppl. 1): S7-S10.
11. Boucher, H.W., G.H. Talbot, J.S. Bradley, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48: 1-12.
12. Styers, D., D.J. Sheehan, P. Hogan, et al. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5: 2.
13. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. 2012. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute
14. Duplessis, C. & N.F. Crum-Cianflone 2011. Ceftaroline: a new cephalosporin with activity against methicillin-resistant staphylococcus aureus (MRSA). Clin. Med. Rev. Ther 3. pii: a2466.
15. Flamm, R.K., H.S. Sader, D.J. Farrell & R.N. Jones 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob. Agents Chemother 56: 2933-2940.
16. Farrell, D.J., M. Castanheira, R.E. Mendes, et al. 2012. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin. Infect. Dis 55: S206-S214.